Skip to main content

Table 2 Response to treatment at 3 months

From: CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy

Response to treatment

n = 78, n (%)

Response at first assessment:

 • Complete response

9 (11)

 • Partial response

16 (21)

 • Stable disease

17 (22)

 • Progression disease

36 (46)

ORR

25 (32)

DCR

39 (50)